Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01327495 · ClinicalTrials.gov registry record · Phase 2
PROS-2 Dose Response Effects of Exogenous Testosterone on the Prostate
A Phase 2 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT01327495: Completed Phase 2 study, sponsored by University of Washington.
NCT01327495 is a Phase 2 study that has completed, run by University of Washington. The registered enrollment target is 62 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01327495, a Phase 2 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
The investigators will conduct a three-month, randomized, placebo-controlled trial comparing the effects of increasing doses of androgen supplementation with Testosterone (T) gel on the prostate in healthy men who are treated with acyline to block gonadal androgen production.
Primary Outcome
To measure intraprostatic dihydrotestosterone \[DHT\] levels
Interventions
- OTHER placebo gel
- OTHER placebo acyline
- DRUG Testosterone 1% gel 1.25 g
- DRUG Testosterone 1% gel 2.5 g
- DRUG Testosterone 1% gel 5.0 g
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2011-10 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
What the finished NCT01327495 record still lists
NCT01327495 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 5 interventions - of which placebo gel is the first listed.
NCT01327495 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01327495 about?
NCT01327495 is a clinical study titled "PROS-2 Dose Response Effects of Exogenous Testosterone on the Prostate". The investigators will conduct a three-month, randomized, placebo-controlled trial comparing the effects of increasing doses of androgen supplementation with Testosterone (T) gel on the prostate in healthy men who are treated with acyline to block gonadal androgen production.
What is the current status of trial NCT01327495?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2011-10. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01327495?
The interventions under investigation include: placebo gel (OTHER), placebo acyline (OTHER), Testosterone 1% gel 1.25 g (DRUG), Testosterone 1% gel 2.5 g (DRUG), Testosterone 1% gel 5.0 g (DRUG).
Who is sponsoring clinical trial NCT01327495?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01327495's enrollment target sits among peer trials
62 1016th of 2000 higher than 975 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia